ERBB2 and breast cancer: A phase 1 dose-escalation study (NCT01304797) evaluated the safety, tolerability, and pharmacokinetics of MM-302 as a monotherapy, in combination with TZM, or TZM plus cyclophosphamide in patients with advanced HER2-positive breast cancer.